Access cutting-edge central sleep apnea comorbid with opioid use treatment through this phase 2 clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Pittsburgh location
Preparing your pre-screening questions…
Access central sleep apnea comorbid with opioid use specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related central sleep apnea comorbid with opioid use treatment provided free
Check if you qualify for this central sleep apnea comorbid with opioid use clinical trial in Pittsburgh, PA
No-Cost Study Care
Local to Pittsburgh
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribute to improved health.
Sponsor: Sanjay R Patel
Yes, this clinical trial (NCT06521476) has an active research site in Pittsburgh, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for central sleep apnea comorbid with opioid use treatment options in Pittsburgh, PA, this clinical trial (NCT06521476) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Pittsburgh research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced central sleep apnea comorbid with opioid use specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all central sleep apnea comorbid with opioid use clinical trials near you to find additional studies recruiting in your area.
See all rheumatoid arthritis clinical trials recruiting in Pittsburgh — not just this study.
Browse Rheumatoid Arthritis Trials in Pittsburgh →